UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213

Breast cancer research and treatment, 2018, Vol.167 (2), p.485-493

2018

Volltextzugriff (PDF)

Preference weights for chemotherapy side effects from the perspective of women with breast cancer

Breast cancer research and treatment, 2013-11, Vol.142 (1), p.101-107

2013

Volltextzugriff (PDF)

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience

Breast cancer research and treatment, 2020-12, Vol.184 (3), p.733-741

2020

Volltextzugriff (PDF)

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

Investigational new drugs, 2013-12, Vol.31 (6), p.1522-1529

2013

Volltextzugriff (PDF)

Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer

Current oncology (Toronto), 2015-02, Vol.22 (1), p.33-48

2015

Volltextzugriff (PDF)

The role of VEGF in triple-negative breast cancer: where do we go from here?

Annals of oncology, 2009-10, Vol.20 (10), p.1615-1617

Dent, S.F.

2009

Volltextzugriff (PDF)

Progress in breast cancer-can we do better?

Current oncology (Toronto), 2018-06, Vol.25 (Suppl 1), p.S7-8

Dent, S F

2018

Volltextzugriff (PDF)

Endocrine therapy for male breast cancer: rates of toxicity and adherence

Current oncology (Toronto), 2010-10, Vol.17 (5), p.17-21

2010

Volltextzugriff (PDF)

Optimal systemic therapy for early breast cancer in women: a clinical practice guideline

Current oncology (Toronto), 2015-03, Vol.22 (Suppl 1), p.S67-81

2015

Volltextzugriff (PDF)

Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline

Current oncology (Toronto), 2015-03, Vol.22 (Suppl 1), p.S95-113

2015

Volltextzugriff (PDF)

Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline

Current oncology (Toronto), 2015-03, Vol.22 (Suppl 1), p.S114-122

2015

Volltextzugriff (PDF)

Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline

Current oncology (Toronto), 2015-03, Vol.22 (Suppl 1), p.S82-94

2015

Volltextzugriff (PDF)

Second primary malignancies following the treatment of early stage ovarian cancer: Update of a study by the National Cancer Institute of Canada—Clinical Trials Group (NCIC—CTG)

Annals of oncology, 2000-01, Vol.11 (1), p.65-68

2000

Volltextzugriff (PDF)

Phase I trial design: Are new methodologies being put into practice?

Annals of oncology, 1996-08, Vol.7 (6), p.561-566

1996

Volltextzugriff (PDF)

Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres

Current oncology (Toronto), 2011-06, Vol.18 (3), p.119-125

2011

Volltextzugriff (PDF)

Ottawa Cardiac Oncology Program wins 2013 Cancer Quality Council of Ontario Innovation Award

Current oncology (Toronto), 2014-06, Vol.21 (3), p.150-150

2014

Volltextzugriff (PDF)

Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience

Current oncology (Toronto), 2012-08, Vol.19 (4), p.e239-243

2012

Volltextzugriff (PDF)

Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer

Lung, 2005-08, Vol.183 (4), p.265-272

2005

Volltextzugriff (PDF)

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group

Breast cancer research and treatment, 2020-12, Vol.184 (3), p.733

2020

Volltextzugriff (PDF)

337PFirst Canadian interim analysis from the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Toxicities and adherence rates of hormone treatment in male breast cancer patients treated at a tertiary care center

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e11613-e11613

2009

Volltextzugriff (PDF)

First Annual Canadian Cardiac Oncology Network Conference

Current oncology (Toronto), 2011-12, Vol.18 (6), p.295-300

2011

Volltextzugriff (PDF)

Sexual distress in early breast cancer (EBC) survivors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e19595-e19595

2010

Volltextzugriff (PDF)

When the BRCA test is negative—Prevention strategies in women who have no detectable mutation (BRCA-) compared to women harboring positive BRCA mutations (BRCA+)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.1534-1534

2008

Volltextzugriff (PDF)

Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methothrexate, and daily prednisone (DalCMP) as therapy for metastatic breast cancer (MBC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.1152-1152

2010

Volltextzugriff (PDF)

1 – 25 von 1.660

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.399)
Mit Volltextzugriff
(1.433)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213

Preference weights for chemotherapy side effects from the perspective of women with breast cancer

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer

The role of VEGF in triple-negative breast cancer: where do we go from here?

Progress in breast cancer-can we do better?

Endocrine therapy for male breast cancer: rates of toxicity and adherence

Optimal systemic therapy for early breast cancer in women: a clinical practice guideline

Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline

Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline

Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline

Second primary malignancies following the treatment of early stage ovarian cancer: Update of a study by the National Cancer Institute of Canada—Clinical Trials Group (NCIC—CTG)

Phase I trial design: Are new methodologies being put into practice?

Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres

Ottawa Cardiac Oncology Program wins 2013 Cancer Quality Council of Ontario Innovation Award

Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience

Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group

337PFirst Canadian interim analysis from the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial

Toxicities and adherence rates of hormone treatment in male breast cancer patients treated at a tertiary care center

First Annual Canadian Cardiac Oncology Network Conference

Sexual distress in early breast cancer (EBC) survivors

When the BRCA test is negative—Prevention strategies in women who have no detectable mutation (BRCA-) compared to women harboring positive BRCA mutations (BRCA+)

Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methothrexate, and daily prednisone (DalCMP) as therapy for metastatic breast cancer (MBC)

Suchergebnisse filtern